Cloning and Expression of \( B.\) \( m\)ellitensis bp26 Gene in \( Lactococcus\) \( lactic\) as a Food Grade Vaccine

Maryam Azizpour Maghvan \(^1\), Parvaneh Jafari \(^1\), Seyed Davood Hoseini \(^2\)\(^,*\), and Ali mohammad Behrozikhah \(^3\)

1. Department of Microbiology, Islamic Azad University, Arak Branch, Arak, Iran
2. Razi Vaccine and Serum Research Institute, Agricultural Research, Education & Extension Organization, Arak, Iran
3. Razi Vaccine and Serum Research Institute, Agricultural Research, Education & Extension Organization, Karaj, Iran

Abstract

**Background:** Brucellosis is still an important health problem in under developing countries and researches for finding efficient vaccine are going on. \( Brucella\) \( m\)ellitensis \( (B.\) \( m\)ellitensis) bp26 gene is a good candidate for brucellosis vaccine and investigations showed that \( Lactococcus\) \( lactic\) \( (L.\) \( lactic)\) with several positive characteristic are attractive for protein expression as a live delivery vectors. These fast growing bacteria need no aeration, are easy to handle, have no exotoxin, endotoxin and protease, so the cost of culturing is inexpensive.

**Methods:** \( B.\) \( m\)ellitensis bp26 gene was cloned in food grade pNZ 8149 vector and expressed in \( L.\) \( lactic\) \( NZ\) 3900.

**Results:** Results showed that we can produce a food-grade recombinant \( L.\) \( lactic\) producing the \( B.\) \( m\)ellitensis BP26 protein.

**Conclusion:** In this study, for Future evaluation about ability of \( L.\) \( lactic\) as a live delivery vector, a food-grade recombinant \( L.\) \( lactic\) producing the \( B.\) \( m\)ellitensis BP26 protein was produced.

**Avicenna J Med Biotech** 2019; 11(3): 264-267

**Keywords:** Brucellosis, Exotoxins, \( Lactococcus lactic\), Vaccines

Introduction

Brucellosis is zoonotic diseases which made health and economic problem in many countries \(^1\). In industrialized nations, because of routine screening of domestic livestock and animal vaccination brucellosis in humans and livestock are relatively uncommon. Up to now human vaccines are available, and current animal vaccines are both virulent in humans and lack clinical efficacy \(^2\). Therefore, an efficient, economical and easily managed vaccine needs to be developed.

Researchers revealed that \( Brucella\) \( m\)ellitensis \( (B.\) \( m\)ellitensis) bp26 gene is a good immunogen and can be candidate for \( Brucella\) spp vaccine \(^3\). This gene encoding the 28 kDa periplasmic protein is named BP26, CP28 or Omp28 and is a target molecule to detect anti-\( Brucella\) antibodies \(^4,5\). To date, \( Lactococcus lactic\) \( (L.\) \( lactic)\) is attractive live delivery vector through mucosal routes for delivering bioactive proteins. \( L.\) \( lactic\) enters through M cells and multiplied within phagocytic cells so releasing and spreading in deeper layer was occurred. Therefore induction of immune responses against \( L.\) \( lactic\) antigens was Getting Started \(^6-10\). PNZ8149 was used as the broad host range vector. This vector produces a cytoplasmic protein and to prevent protein removal by digestive enzymes or by other factors in the digestive tract, this protein was not designed to be secreted or attached to the cell surface of bacteria. Therefore, after entering of this recombinant bacterium through the M cells and up taking via phagocytic cells, the probability of induction the immune system, through BP26 protein, is higher \(^11\).

In this study for first time, \( B.\) \( m\)ellitensis bp26 gene was cloned into the PNZ 8149 vector and expressed in \( L.\) \( lactic\) \( NZ\) 3900 for used as a research experimental tool to find a good vaccine candidate.

Materials and Methods

**Bacterial strains and growth conditions**

Any bacterial strains and plasmids used in this study are showed in table 1. All \( L.\) \( lactic\) strains were grown at 30°C on M17 media (Merck, Germany) containing 0.5% glucose (M17-gluc) or lactose (M17-lact). All \( Escherichia coli\) \( (E.\) \( coli)\) DH15a strain were grown at 37°C on Luria-Bertani (LB) medium (Merck, Germany) containing 50 μg/ml Ampicillin or 50 μg/ml kanamycin.
Amplification of bp26 gene

To amplify the bp26 gene, one pair of PCR primers was designed based on sequences published in Gene Bank (accession No. JF918758.1), and the restriction endonuclease sites of XbaI and SphI were added to both ends of the modified bp26 protein gene e based on the structure of PNZ8149 (forward: GCATGCATGA ACACCTCGTG and reverse: TCTAGATTACTTGAT TTCAAAAAACGAC). Template DNA (pET28a+bp26) preserved by Our lab 3. The PCR was performed initial denaturation at 95°C for 2 min, followed by 34 cycles of 95°C for 1 min, 58°C for 1 min, and 72°C for 1 min. With Extra polymerization in 72°C for 30 min. The PCR product consisting 753 bp was checked using agarose gel electrophoresis and then purified using a Fermentas Silica Bead DNA Gel Extraction Kit.

Cloning and transformation

The PCR product was cloned in to pTZ57R/T vector and transformed in E. coli DH5α competent cells. The recombinant pTZ57R/T plasmid was extracted and digested with two restriction enzymes (SphI /NEB Bio lab and XbaI/Fermentas Digestion Enzyme). At the same time the pNZ8149 plasmid was digested with both SphI and XbaI and purified. The purified desire was inserted into the pNZ8149. Competent L. lactis NZ39000 cells were then electro-transformed with the recombinant plasmids (Gene e-Pulsar; Bio-Rad, Hercules, CA, USA) and cultured on ELLiker agar-lac bromocresol purple and incubated at 30°C for 48 hr. Transformants harboring the recombinant plasmids were verified through enzymatic digestion and PCR.

Expression of recombinant protein

Expression performed according to MoBiTec NICE_Expression_System and analyzed on 10% SDS-PAGE. To confirm the accuracy of the SDS-Page and protein expression, Western Blot was performed with Nitrocellulose Membrane (Sigma) and using the Trans-Blot SD cell (BIO-RAD). After blocking with TBST (tris-buffered saline, 0.05% Tween-20) buffer containing 5% skimmed milk at 4°C overnight, the membranes were incubated with a mouse IgG monoclonal antibody, anti-OMP28, (MyBioSource, Inc, USA) at a dilution 1:500 in phosphate-buffered saline (PBS) at a 37°C for 60 min. Then, the blots were washed and incubated with 1:2000 dilution of HRP-conjugated rabbit anti-mouse IgG (MyBioSource, Inc, USA) for 60 min. Binding was visualized using diaminobenzidine (Merck), according to the manufacturer’s instruction.

Results

PCR screening

Results showed that the expected DNA band of the bp26 gene had been amplified; the PCR product was approximately 753 bp in length plus the 12 bp restriction sites (Figure 1).

Digestion screening

Double-digestion confirms the size of bp26 gene (Figure 2).

Induced expression of the recombinant L. lactis

Results of bp26 gene expression on SDS-PAGE; as it is evident in the figure, with increasing Nisin (1 ng/ml) addition time, the amount of protein expression also increases. Protein production increase with Nisin and in 5th hr the high level of protein production was seen. Results indicated that the molecular weight of the expressed recombinant protein was approximately 28 kDa (Figure 3).

Western blot results showed that the produced protein was the B. melitensis omp28 (Figure 4). The result show that the binding of BP26 protein and its antibody occurred.
Cloning and Expression of *B. melitensis* bp26 gene in *Lactococcus lactis* as a Food Grade Vaccine

Figure 2. Double-digestion on 1% agarose gel: Lane 1; pNZ 8149, Lane 2; Fermentas 1 Kb DNA Ladder, Lane 3; pNZ 8149+ bp26 double-digestion.

Figure 3. bp26 gene expression on SDS-PAGE: Lane 1; L. lactis with pNZ 8149 vector, Lane 2; L. lactis 3900, Lane 3; Fermentas protein Ladder, Lane 4; transformed L. lactis with recombinant pNZ 8149+bp26 vector before adding Nisin, Lane 5; transformed L. lactis with recombinant pNZ 8149+bp26 vector 1 hr after adding Nisin, Lane 6; transformed L. lactis with recombinant pNZ 8149+bp26 vector 3 hr after adding Nisin, Lane 7; transformed L. lactis with recombinant pNZ 8149+bp26 vector 5 hr after adding Nisin.

Figure 4. BP26 production was approved by western blot analysis. Lane 1; BP26 before adding nisin, Lane 2; BP26 production 1 hr after adding nisin, Lane 3; BP26 production 3 hr after adding nisin, Lane 4; BP26 production 5 hr after adding nisin.

Discussion

Brucellosis is a worldwide zoonotic disease, which remain an important public health concern and causes economic losses in endemic areas. Vaccination is the most possible way to reduce the transmission in domestic animal herds and humans. The infectious cycles of most pathogenic micro-organisms initiate from mucosal surfaces. So, if colonization and invasion of infectious agents stopped in this stage, the infection does not happen. For this purpose, a vaccine must be made to stimulate mucosal and cellular immunity. Today, investigations showed that using Lactic Acid Bacteria (LAB) as a live delivery vectors for antigens can induce mucosal immunity and one of the most important candidates to produce mucosal vaccines. In this investigation, we used *L. lactis* 3900 as a gene delivery vehicle. Despite the fact that *L. lactis* is a non-commensal and non-colonizing bacterium at the level of the gastrointestinal tract, it can be easily taken up by M cells, and exhibits adjuvant/immune potentiating activity. As *Brucella* infections involve mainly bacterial entry through the mucosal routes, the development of successful approaches for oral vaccination could radically alter the current scene of brucellosis. Most published studies have evaluated the use of live vectors expressing *Brucella* antigens for vaccine delivery at the mucosal gut. At present, several recombinant proteins of *Brucella* have been evaluated as oral vaccine with *L. lactis* and sufficient evidence showed that they can induce protective immunity in mice. For example, in 2002, Luciana A. Ribeiro et al expressed *Brucella abortus* L7/L12 gene in *L. lactis*, under the nisin-inducible promoter. In another work, Daniela S. Pontes et al in 2003, revealed that a recombinant *Lactococcus lactis* strain producing L7/L12 under the control of nisin inducible promoter when orally administered to BALB/c mice, they could induced local humoral immune response and detected significant levels of anti-L7/L12 specific IgA in feces.

In 2012 DarwinSáez et al, transformed *Brucella abortus* (*B. abortus*) Cu-Zn Superoxide dismutase (SOD) in *L. lactis* revealed that orally vaccinated mice protected against challenge with the virulent *B. abortus* 2308 strain.

Conclusion

According to the investigations which mentioned above and considering that *B. melitensis* BP26 is a good immunogenic protein, in this study, we successfully constructed a food-grade recombinant *L. lactis* producing the *B. melitensis* BP26 protein for future researches about induction of immune response by this protein.

Acknowledgement

The authors thank Dr. Behrozikhah, Razi Vaccine and Serum Research Institute, Agricultural Research, Education & Extension Organization, Karaj, Iran and Dr. Tavangar, Razi Vaccine and Serum Research Institute, Agricultural Research, Education & Extension Organization, Karaj, Iran for their constant support and guidance.

References


